Double Test
The blood test component measures two specific markers: pregnancy-associated plasma protein A (PAPP-A) and human chorionic gonadotropin (hCG). Abnormal levels of these hormones can indicate an increased risk for genetic issues. Simultaneously, the ultrasound measures the nuchal translucency, which is the fluid-filled space at the back of the baby's neck. A thicker measurement here is often associated with a higher risk of chromosomal disorders.
A double test is a prenatal screening performed during the first trimester of pregnancy to assess the risk of chromosomal abnormalities in the fetus. It typically occurs between the 11th and 14th weeks of gestation. This screening combines a maternal blood test with an ultrasound examination to provide a statistical probability regarding conditions like Down syndrome and Edwards syndrome. double test
It is important to understand that the double test is a screening, not a diagnostic tool. A "high risk" result does not mean the baby has a condition; rather, it suggests that further diagnostic testing, such as amniocentesis or chorionic villus sampling (CVS), may be warranted. Conversely, a "low risk" result provides reassurance but does not guarantee the absence of all genetic conditions. The blood test component measures two specific markers:
The compared to NIPT (Cell-free DNA)?
